MD

Pediatrix is a textbook margin-driven turnaround masquerading as a shrinking business. Revenue fell 4.9% to $1.91B in FY2025, the fourth straight year of flat-to-down top line ($2.01B in 2024 → $1.91B), yet operating income jumped 403.9% to $209M and net income swung from a -$99.1M loss in 2024 to +$165M. The MD&A's emphasis on 'transformation and restructuring' — position eliminations across shared services and revenue-cycle-management transition — plus tuck-in neonatology/MFM acquisitions tells you the revenue decline is largely deliberate pruning of unprofitable contracts, not lost demand. The result is a real operating margin of 10.9%, an 8.6% net margin, and a 19.1% ROE off a still-negative -$83.2M accumulated deficit that is rapidly being repaired.

The valuation does not price this in. At $24.69 the stock trades at 12.7x FY diluted EPS of $1.94 and just 1.1x sales. The cash engine is the real draw: operating cash flow rose 31.2% to $271M against only $21.8M of D&A, implying an asset-light physician-services model that converts most of that OCF to free cash — roughly a low-double-digit FCF yield on the $2.05B market cap. Management is leaning into it, repurchasing $86.7M of stock in 2025 (with $166.2M still authorized under the new August 2025 $250M program), and the share count is already down 3.3%. Net leverage is modest — $611M long-term debt against $375M cash (up 63.2%) and $271M of annual OCF.